

**CURRICULUM VITAE**

**C. PIERS CLIFFORD MD BA MBBS FRCP**

**January 2020**

**PERSONAL:**

**NAME:** Christopher Piers Clifford

**DATE OF BIRTH:** 9<sup>th</sup> March 1963

**ADDRESS:** 26, Chiswick Lane, London W4 2JG

**TELEPHONE:**       **Home:**       0208 9954022  
                             **Work:**       01494 425004  
                             **Mobile:**   07747 015208

**NATIONALITY:** British

**GMC Registration No:** 3259797

**EDUCATION:**

1974-1980                   Open Scholarship to Christ's Hospital, Horsham, Sussex.

1981-1984                   Open Scholarship to St. John's College, Oxford.

1984-1987                   St. Mary's Hospital Medical School, London.

**QUALIFICATIONS:**

1984                       BA Hons (Oxon) First Class

1987                       MB BS (London)

1998                       MD (London)

2000 (February)       CCST Cardiology

2007                       FRCP (UK)

2014                       Cardiff University CUBS certificate for medico-legal work

## **PRIZES & AWARDS:**

Scholarship to St. John's College, Oxford. October 1982.

College Book Prize for Physiological Sciences. July 1984.

Prize from the Martin Wronker Fund, Oxford. July 1984.

First Class Honours in Physiological Sciences. July 1984.

Davenport Award (Bucks Healthcare) July 2014

PENN award for cardiac rehabilitation 2014

CUBS certificate (Cardiff University) 2014

HSJ Innovation Award 2015

Finalist HSJ Value in Healthcare Award 2014

Finalist Pharmatimes NHS Research Site of the Year 2016

Award from Dame Sally Davies for delivering NIHR commercial research 2015

## **PRESENT APPOINTMENTS:**

Oct 1999 – Present

### **Consultant Cardiologist**

Buckinghamshire Healthcare NHS Trust

Imperial Hospitals NHS Trust (Hammersmith Campus)

May 2014-Present

NIHR CRN (Thames Valley and South Midlands)  
subspeciality lead for Cardiology

## **PREVIOUS APPOINTMENTS:**

May 2014-May2018

Elected Council Member of the British Cardiovascular Society. On Academic and Research Committee

Aug 1991-Oct 1999

Cardiology registrar, MRC research fellow and Senior Registrar at Hammersmith Hospital

Feb 1990-Aug 1991

Cardiology registrar at Harefield Hospital

Aug 1988-Feb 1990

SHO rotation, John Radcliffe Hospital, Oxford (Renal Unit, Cardiology and Geriatrics)

Aug1987- Aug 1988

House Officer, St Mary's Hospital, London  
(Gastroenterology and General Surgery)

## **CLINICAL EXPERIENCE:**

I have been a Consultant Cardiologist for 19 years and have a wide and extensive experience in General Cardiology as well as in coronary intervention. At present I perform 200 angioplasties per year, mainly involving coronary stenting, which places me in the upper decile for interventional procedures in the UK. My areas of particular interest are in primary angioplasty and bifurcation stenting. I am on a primary angioplasty on call rota at the Hammersmith Hospital. I continue to provide a pacing and angiography service. My other areas of interest are in the mechanisms of hypertension and LVH, as well as a particular interest in the management of atrial fibrillation. I have run hypertension clinics for the last 19 years.

## **RESEARCH EXPERIENCE:**

My doctorate investigated the molecular mechanisms of left ventricular hypertrophy in hypertensive adults. Since I became a consultant I have participated in multi-centre trials including IONA, SENIORS, OVERTURE, EPICOR, DAPT and Leaders Free studies. I am PI for 20 studies at present, most of which are commercial studies on the NIHR portfolio. I received recognition in 2015 from Dame Sally Davies, the Chief Medical Officer, for my contribution to NIHR research and won an award from the Thames Valley CRN as the 'high performing research team'

At present my primary interest is in the use of digital technology to deliver better health outcomes for patients at reduced cost to the healthcare system.

I am now actively involved on the Council of the British Cardiovascular Society in promoting cardiovascular research in the UK, via the Academic and Research committee. I am on the cardiovascular research committee at Imperial Hospitals NHS Trust and have already set up 4 commercial trials at the Hammersmith, since I started in July 2016.

I am the sub-speciality lead for cardiovascular research for the NIHR CRN for Thames Valley and South Midlands.

My research fields are diverse but include-

Hypertension (especially the use of renal denervation)

Atrial fibrillation- Gloria, Re-DUAL, Pioneer, Prefer AF, ETNA AF.

Heart Failure- Relax 2 and in collaboration with Janssen, PARAGON, Ariadne.

Novel lipid lowering drugs- Oddysey Outcomes, Oddysey Diabetes and Orion

Coronary stenting- e-Ultimaster, MASCOT, DAPT, Leaders Free

Cardiac rehabilitation- Care for Today

Heart Attack- PICSO

I also develop and lead investigator initiated studies

I employ 3 full time research nurses at Wycombe Hospital, a trial coordinator and a data administrator, predominantly funded by NIHR.

### **MANAGEMENT EXPERIENCE:**

I am the Clinical Lead for Cardiology at Buckinghamshire Hospitals NHS Trust, managing a budget in excess of £10,000,000.

As cardiology lead I have developed a highly successful unit. We now perform 1400 angiograms, 540 angioplasties and 260 pacemakers through a single catheter laboratory. Prior to my arrival all this work was performed elsewhere leading to delays in treatment and excessive lengths of stay. Our bed stock has diminished by 50% as a result. We generate more income and profit for the Trust as an SDU than any other in the Hospital. I have maintained and developed strong links with our surrounding Tertiary Centres to deliver high quality care to Buckinghamshire patients.

I was previously the Chairman of the Division of Medicine. I delivered a 15% reduction in the Medical budget without any loss of service. We developed our hyperacute services to include daytime primary angioplasty and a HASU. We streamlined the urgent care pathway to reduce admissions and encourage early discharge through a short stay medical assessment ward.

### **TEACHING EXPERIENCE:**

I teach undergraduates from the Oxford Deanery and have an active involvement in the F1/F2 teaching programs. I am a trainer in coronary angioplasty and regularly lecture on interventional cardiology. I am on advisory boards for many different device and pharmaceutical companies.

### **MEDICOLEGAL EXPERIENCE:**

I prepare approximately 35 reports per year- 85% for the Claimant and 15% for the Defendant. These cover the whole range of clinical cardiology.

I would expect to provide the report within 2 weeks of receiving instructions and the medical notes.

I received training in medicolegal work from Bond Solon and have attained the Cardiff University CUBS certificate in medicolegal work. I attended the Bond Solon annual conference 2015-2018

### **PUBLICATIONS:**

1. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA. [Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention \(THEMIS-PCI\): a phase 3, placebo-controlled, randomised trial](#). Lancet. 2019 Aug 30;. doi: 10.1016/S0140-6736(19)31887-2. [Epub ahead of print] PubMed PMID: 31484629.
2. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Golland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stepińska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C. [Effects of Serelaxin in Patients with Acute Heart Failure](#). N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291. PubMed PMID: 31433919.
3. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG. [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](#). Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. PubMed PMID: 31272931.

4. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM. [Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](#). *N Engl J Med*. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. PubMed PMID: 30403574.
5. de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R. [1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration](#). *JACC Cardiovasc Interv*. 2018 Oct 8;11(19):1969-1978. doi: 10.1016/j.jcin.2018.04.038. PubMed PMID: 30286855.
6. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP. [Percutaneous coronary intervention in stable angina \(ORBITA\): a double-blind, randomised controlled trial](#). *Lancet*. 2018 Jan 6;391(10115):31-40. doi: 10.1016/S0140-6736(17)32714-9. Epub 2017 Nov 2. PubMed PMID: 29103656.
7. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH. [Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation](#). *N Engl J Med*. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27. PubMed PMID: 28844193.
8. McCartan F, Bowers N, Turner J, Mandalia M, Kalnad N, Bishop-Bailey A, Fu J, Clifford P. [Introduction of a novel service model to improve uptake and adherence with cardiac rehabilitation within Buckinghamshire Healthcare NHS Trust](#). *BMC Cardiovasc Disord*. 2017 Jul 11;17(1):184. doi: 10.1186/s12872-017-0606-2. PubMed PMID: 28697722; PubMed Central PMCID: PMC5504558.

9. Mittal TK, Pottle A, Nicol E, Barbir M, Ariff B, Mirsadraee S, Dubowitz M, Gorog DA, Clifford P, Firoozan S, Smith R, Dubrey S, Chana H, Shah J, Stephens N, Travill C, Kelion A, Pakkal M, Timmis A. [Prevalence of obstructive coronary artery disease and prognosis in patients with stable symptoms and a zero-coronary calcium score](#). *Eur Heart J Cardiovasc Imaging*. 2017 May 1;18(8):922-929. doi: 10.1093/ehjci/jex037. PubMed PMID: 28379388; PubMed Central PMCID: PMC5837484.
10. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY. [The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2](#). *J Am Coll Cardiol*. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061. PubMed PMID: 28209218.
11. Sharp AS, Davies JE, Lobo MD, Bent CL, Mark PB, Burchell AE, Thackray SD, Martin U, McKane WS, Gerber RT, Wilkinson JR, Antonios TF, Doulton TW, Patterson T, Clifford PC, Lindsay A, Houston GJ, Freedman J, Das N, Belli AM, Faris M, Cleveland TJ, Nightingale AK, Hameed A, Mahadevan K, Finegold JA, Mather AN, Levy T, D'Souza R, Riley P, Moss JG, Di Mario C, Redwood SR, Baumbach A, Caulfield MJ, Dasgupta I. [Renal artery sympathetic denervation: observations from the UK experience](#). *Clin Res Cardiol*. 2016 Jun;105(6):544-52. doi: 10.1007/s00392-015-0959-4. Epub 2016 Jan 22. PubMed PMID: 26802018; PubMed Central PMCID: PMC4882343.
12. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L. [Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention](#). *JAMA*. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. PubMed PMID: 27022822; PubMed Central PMCID: PMC5408574.
13. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC. [Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk](#). *N Engl J Med*. 2015



Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14. PubMed PMID: 26466021.

14. Alabas OA, West RM, Gillott RG, Khatib R, Hall AS, Gale CP. [Evaluation of the Methods and Management of Acute Coronary Events \(EMMACE\)-3: protocol for a longitudinal study](#). *BMJ Open*. 2015 Jun 23;5(6):e006256. doi: 10.1136/bmjopen-2014-006256. PubMed PMID: 26105029; PubMed Central PMCID: PMC4480017.
15. Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G. [First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension](#). *Hypertension*. 2015 Apr;65(4):766-74. doi: 10.1161/HYPERTENSIONAHA.114.05010. Epub 2015 Feb 17. PubMed PMID: 25691618.
16. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. [Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial](#). *JAMA*. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. PubMed PMID: 25781440; PubMed Central PMCID: PMC4481320.
17. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. [Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents](#). *N Engl J Med*. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16. PubMed PMID: 25399658; PubMed Central PMCID: PMC4481318.
18. Iqbal MB, Ilesley C, Kabir T, Smith R, Lane R, Mason M, Clifford P, Crake T, Firoozi S, Kalra S, Knight C, Lim P, Malik IS, Mathur A, Meier P, Rakhit RD, Redwood S, Whitbread M, Bromage D, Rathod K, MacCarthy P, Dalby M. [Culprit vessel versus multivessel intervention at the time of primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction and multivessel disease: real-](#)

- [world analysis of 3984 patients in London](#). *Circ Cardiovasc Qual Outcomes*. 2014 Nov;7(6):936-43. doi: 10.1161/CIRCOUTCOMES.114.001194. Epub 2014 Nov 4. PubMed PMID: 25371542.
19. Wilkins MR, Roses AD, Clifford CP. [Pharmacogenetics and the treatment of cardiovascular disease](#). *Heart*. 2000 Oct;84(4):353-4. doi: 10.1136/heart.84.4.353. PubMed PMID: 10995394; PubMed Central PMCID: PMC1729456.
  20. Clifford CP, Nunez DJ. [Mutation profile in the beta-myosin heavy chain gene in hypertensive hypertrophic heart disease](#). *Hum Mutat*. 1999 Sep 19;14(3):272. doi: 10.1002/(SICI)1098-1004(1999)14:3<272::AID-HUMU20>3.0.CO;2-Y. PubMed PMID: 10477493.
  21. Clifford CP, Nunez DJ. [Human beta-myosin heavy chain mRNA prevalence is inversely related to the degree of methylation of regulatory elements](#). *Cardiovasc Res*. 1998 Jun;38(3):736-43. doi: 10.1016/s0008-6363(98)00058-3. PubMed PMID: 9747442.
  22. Adams DA, Murray S, Clifford CP, Rendell NB, Davies DS, Taylor GW. [Analysis of terfenadine in human plasma using microbore high-performance liquid chromatography-electrospray ionisation mass spectrometry](#). *J Chromatogr B Biomed Sci Appl*. 1997 Jun 6;693(2):345-51. doi: 10.1016/s0378-4347(97)00083-2. PubMed PMID: 9210438.
  23. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. [The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice](#). *Eur J Clin Pharmacol*. 1997;52(4):311-5. doi: 10.1007/s002280050296. PubMed PMID: 9248771.
  24. Nunez DJ, Clifford CP, al-Mahdawi S, Dutka D. [Hypertensive cardiac hypertrophy-is genetic variance the missing link?](#) *Br J Clin Pharmacol*. 1996 Jul;42(1):107-17. doi: 10.1046/j.1365-2125.1996.37315.x. Review. PubMed PMID: 8807151; PubMed Central PMCID: PMC2042633.
  25. Clifford CP, Nunez DJ. [5HT 2a receptor T102C polymorphism and schizophrenia](#). *Lancet*. 1996 Jun 29;347(9018):1830. PubMed PMID: 8667936.

26. Clifford CP, Eykyn SJ, Oakley CM. [Staphylococcal tricuspid valve endocarditis in patients with structurally normal hearts and no evidence of narcotic abuse](#). QJM. 1994 Dec;87(12):755-7. doi: 10.1093/oxfordjournals.qjmed.a068894. PubMed PMID: 7859052.
  
27. Donnelly LE, Boyd RS, Clifford CP, Olmos G, Allport JR, Lo G, MacDermot J. [Endogenous substrates and functional role of eukaryotic mono\(ADP-ribosyl\) transferases](#). Biochem Pharmacol. 1994 Nov 1;48(9):1669-75. doi: 10.1016/0006-2952(94)90450-2. Review. PubMed PMID: 7980634.
  
28. Clifford CP, Davies GJ, Scott J, Shaunak S, Sarvill J, Schofield JB. [Tuberculous pericarditis with rapid progression to constriction. Prompt diagnosis and treatment are needed](#). BMJ. 1993 Oct 23;307(6911):1052-4. doi: 10.1136/bmj.307.6911.1052. PubMed PMID: 8251782; PubMed Central PMCID: PMC1679225.
  
29. Clifford CP, Crook DW, Conlon CP, Fraise AP, Day DG, Peto TE. [Impact of waterborne outbreak of cryptosporidiosis on AIDS and renal transplant patients](#). Lancet. 1990 Jun 16;335(8703):1455-6. doi: 10.1016/0140-6736(90)91478-s. PubMed PMID: 1972222.